You are here

Home » Content

HEMODİYALİZDEKİ SON DÖNEM BÖBREK HASTALARİNDA ERITROPOIETIN TEDAVİSİNİN KAN LIPID VE LIPOPROTEIN DÜZEYLERİN E ETKİLERİ

THE EFFECTS OF ERYTHROPOIETIN TREATMENT ON BLOOD LIPID AND LIPOPROTEIN LEVELS IN CHRONIC RENAL FAILURE PATIENTS ON HEMODIALYSIS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1996

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
The correction of anemia in hemodialysis patients with erythropoietin increases appetite, anabolic ef¬fects, and improves physical, psychologyical activities and endocrine functions. As the sense of wellbeing improves, the patients increase food intake and, fre¬quently, their compliance with dietary resriction may decrease. Plasma lipid abnormalities are common among patients undergoing hemodialysis. Those pati¬ents, particulary are prone to diffuse atherosclerosis. There are few and conflicting reports about the ef¬fects of erythropoietin on the lipid profile. For these reasons it would be interesting to know if long-term treatment with erytropoietin could induce changes in the lipid profile of hemodialysis patients. Lipid patterns in 23 patients taking erythropoie-tin, dialysed 63.6±7.0 months and in 25patients without erythropoietin and dialysed 59.5+9.3 months were analysed. In the patients taking erythropoietin; se¬rum triglycerides, LDL cholesterol, apolipoprotein Al, apolipoprotein B levels were higher than in the patients without erythropoietin (p<0.001). Total cho¬lesterol, lipoprotein cholesterol levels were not signi¬ficantly different between the two groups (p<0.05). The differences between the two groups and the hig¬herprevalence of "atherogenic" levels (i. e<90mgldl) of this lipoprotein in the patients who were not taking erythropoietin (p<0.01). We conclude that long-term treatment with eryt-hropoietin changes some lipid patterns and improves serum aapolipoprotein Al levels in hemodialysis pati¬ents.
Bookmark/Search this post with
Abstract (Original Language): 
Hemodiyaliz tedavisi gören son dönem böbrek hastalarında aneminin tedavisinde kullanıllan eritropoietin'in iştahı ve gıda alınımım artırdığı, fiziksel, psikolojik ve endokrin fonksiyonları düzelttiği, anabolik olayları iyileştirdiği gösterilmiştir. Hemodiyaliz has¬talarında lipid bozuklukları olup, hastalar arterioskle-roz'a meyillidirler. Eritropoietin'in kan lipid ve lipoprotein düzeyine etkisini gösterir çok az ve çelişkili raporların olması, eritropoietin'in kan lipid ve lipopro-tein düzeylerine etkisinin bilinmesinin yararlı ve ilginç olabileceğini düşünerek; 63.6+7.0 ay düzenli hemodiyaliz programında olan ve eritropoietin kullanan 23 hasta ile 59.5±9.3 ay hemodiyaliz programında olan ve eritropoietin kullanmayan 25 hasta çalışmaya alındı. Eritropoietin alan hasta grubun trigliserid, LDL kolesterol, Apolipoprotein AL, ve apolipoprotein B düzeyleri eritropoietin almayan hasta grubuna kıyasla eritropoietin alanlarda yüksek bulundu (p<0.001). Total kolesterol, HDL kolesterol ve lipoprotein (a) düzeyleri bakımından gruplar arasında fark yoktu (p>0.05). Kan lipid ve lipoprotein düzeyleri ile diyaliz süreleri arasında bir fark bulunamadı (p>0.05). Arterioskleroz risk faktörlerinden olan serum Apolipoprotein Al dü¬zeyinin 90mgldl altında olması, eritropoetin tedavisi almayan grupta dahafazlaydı (p<0.001). Sonuç olarak Eritropoietin 'in kan lipid ve lipopro-tein düzeylerini etkilediği, arterioskleroziz risk faktör¬lerinden olan serum apolipoprotein Al düzeyinde iyi¬leşme sağladığı gözlendi.
FULL TEXT (PDF): 
PDF icon pdf_tndt_140.pdf
  • 2
72-75
  • Turkish

REFERENCES

References: 

1. Brenner BM, Rector FC. Organ System Alterations and Response to hemodialysis: Lipid Abnormalities. The Kidney, Philedelphia, Saunders, Vol 2, P 2238, 1991.
2. Jacobsan HR. Chronic renal failure: Pathophysiology, Lancet 1991; 338: 419-423.
3. Ma K.W, Greene EL, Raji L. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. AmJ. Kidney Dis. 1992; 19: 505-513.
4. Delano BG. Improvoments in quality of life following treatment with human recombinant erythropoetin in anemic hemodialysis patients. Am. J. Kidney Dis. 1989;
14(2): 14-18.
5. Eschbach JW, Adamson JW. Guidelines for recombinant human erythropoetin therapy. Am. J. Kidney Dis.1989;
14(2): 14-18.
6. Casati S,"Passerini P, Campise MR, Graziani G, Cesana B, Perisic M, Pontinelli C. Benefist and risk of protrac¬ted with hemodialysis. Br. Med. J.1987; 295: 1017¬1020.
7. Mat. O, Stolear JC, Georges B. Blood lipid profile in he-modialysis patients treated with erytropoctin. Nephrol
dial Transplant 1990; 5; 474.
8. Prata MM, Sansa FFT, Barbas JM, Rodriques MC. Blo¬od lipids in hemodialysis patients treated with erythropo-
ietin. Nephrol dial Transplant 1990; 5; 474.
9. Viron B, Donsimoni R, Michel C, Al Kayat R, Mignon F. Effect of recombinant human erythropoitin on nutritu-anal status and plasma liipids in uremic patients, (abs¬tract) Nephron 1992; 60: 249.
10. Pollock CA, Wyndham R, Collett PV, Elder G, Field
MJ, Kalowski S, Lawrence JR, Weugh DA and George CRP. Effects of erythropoietin therapy on the lipid profi¬le in end-stage renal failure. Kidney Int. 1994; 45: 897¬902.
11. Gordon T, Castelli WP, Hijortland MC, Kannel WB,
Drawber TR. High-density lipoprotein as a protective factor againts coronary artery disease. The framinham
Study. Am J Med.1988; 62: 707-714.
12. The expert Panel Report of the national Cholesterol Education Program: Expert Panel on the detection, evaluati¬on, and treatment of high blood cholesterol in adults. Arch Intern Med.1988; 148: 36-69.
13. Sniderman AD: Apolipoprotein B and apolipoprotein Al as a 4: 244-30,1988
14. Alberts JJ, Brunzeell JD, Knopp Rh. Apoprotein measu¬rements and their clinical applications. Clin. Lab. Med. 1989; 9: 137-152
15. Dahlen G, Guyton JR, Arrar M, Farmer JA, Kautz JA, Gotto AM Jr. Association of levels of lipoprotein (a), Plasma lipids and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74:78-765.
16. Rhoads GG, Dahlon G, Berg K, Morton NE, Danrenberg AL. Lp (a) Lipoprotein as a risk factor for mycardial in¬farction. JAMA 1986; 256: 2540-2544.
17. Kuyl JM, Mendelsohn D. Observed relationship between ratios HDL cholesterol/total cholesterol and apolipoprotein Al/apolipoprotein B. Clin. Biochem.1992; 25: 313¬316.
18. Appel G. Lipid abnormal lities in renal disease. Kidney
Int.1991; 39: 169-183.
19. Rostand SG, Brunzell JD, Cannon RO, Victor RG. Car¬diovascular complications in renal failure. J.Am.Soc.
Nephrol. 1991; 2: 1053-1062.

Thank you for copying data from http://www.arastirmax.com